ClinicalTrials.gg
RecruitingNCT06922526Updated Apr 30, 2025

Pacemaker-related Tricuspid Regurgitation Progression and Long-term Outcomes

An observational study in Tricuspid Regurgitation and Pacemaker, sponsored by Haiyan Wang. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-30.

Sponsored by Haiyan Wang · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Tricuspid Valve Insufficiency with a site in China — 19 open to participants now, 21 under way, none of them phase 3. Tricuspid Valve Insufficiency · China.

Planned enrollment
10th of 12
200 · median 2,320
Started
2025
with 3 others
Observational
12 of 28
10 open now
Primary completion
2026-03
later than 3 of 20 live
Registered
19th of 28
by date

Among the 28 studies in Tricuspid Valve Insufficiency with a site in China, this one is the 10th largest by planned enrollment of the 12 observational ones that give a count, is one of 4 that started in 2025, is one of 12 observational ones, reaches primary completion later than 3 of the 20 other live ones, and was the 19th registered.

Tricuspid Valve Insufficiency

229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

Browse Tricuspid Valve Insufficiency studies →

Open to participants now

19 of the 28 studies in Tricuspid Valve Insufficiency with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Tricuspid Valve Insufficiency with a site in China, or all of them as a file.
02

Study summary

Tricuspid regurgitation (TR) is a common complication following cardiac implantable electronic device (CIED) implantation, with severe TR being associated with increased rates of heart failure hospitalization and all-cause mortality, significantly impairing patients' quality of life. With technological advancements, physiological pacing modalities have demonstrated superior clinical efficacy and safety profiles compared to conventional pacing methods.

This study aims to evaluate predictors of adverse outcomes and TR progression in CIED recipients under different pacing modalities, thereby providing clinical guidance for high-risk patients.

Read the detailed description

This retrospective study analyzed patients undergoing pacemaker implantation from January 2015 to March 2025, stratified by pacing modality (right ventricular/conduction system/biventricular pacing) and TR progression (worsened [≥1-grade increase] vs non-worsened TR).

The protocol included: (1) 3D echocardiographic assessment of TR mechanisms, (2) quantitative fluoroscopic analysis of lead parameters (tension, mobility, angulation), (3) multivariable regression evaluating pacing modes and TR progression on clinical outcomes, and (4) documentation of device-related complications (lead dislodgement/infection) and heart failure rehospitalization.

03

Conditions studied

  • Tricuspid Regurgitation
  • Pacemaker
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients after cardiac pacemaker implantation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients
  2. Patients with an implantable electronic heart device (CIEDs)
  3. The patient underwent pacemaker implantation at Qianfoshan Hospital between 2015 and 2025

Exclusion criteria

Exclusion Criteria:

  1. Patients with severe tricuspid regurgitation or those who have undergone tricuspid valve surgery or interventional treatment prior to pacemaker implantation
  2. Patients with severe valvular heart disease, congenital heart disease, or arrhythmias
  3. Patients with single-chamber pacemakers or poor images
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Right ventricular pacing group

    Device: Pacemaker implantation

  • conduction system pacing group

    Device: Pacemaker implantation

  • biventricular pacing group

    Device: Pacemaker implantation

  • TR progression group
  • non-TR progression group

Interventions

  • DevicePacemaker implantation

    Pacemaker implantation methods include right ventricular pacing, biventricular pacing, conduction system pacing

06

What researchers measure

Primary outcomes

  1. Tricuspid regurgitation progression(Progression of tricuspid regurgitation ≥ grade 0.5)

    Grading of tricuspid regurgitation severity:Grade 0: None Grade 0.5: Trace Grade 1: Mild Grade 1.5: Mild to moderate Grade 2: Moderate Grade 2.5: Moderate to severe Grade 3: Severe

    Time frame: Mean follow-up of 1 year

Secondary outcomes

  1. Heart Failure Readmission Rate After CIED Implantation

    Time frame: Mean follow-up of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Hoke U, Auger D, Thijssen J, Wolterbeek R, van der Velde ET, Holman ER, Schalij MJ, Bax JJ, Delgado V, Marsan NA. Significant lead-induced tricuspid regurgitation is associated with poor prognosis at long-term follow-up. Heart. 2014 Jun;100(12):960-8. doi: 10.1136/heartjnl-2013-304673. Epub 2014 Jan 21. PubMed 24449717 ↗
  • Li X, Fan X, Wang Q, Wang Z, Zhu H, Li H, Wang H, Liu Z, Yao Y. Tricuspid regurgitation following pacemaker implantation for bradycardia: a two-year study comparing different pacing strategies. Chin Med J (Engl). 2023 Oct 20;136(20):2508-2510. doi: 10.1097/CM9.0000000000002825. Epub 2023 Aug 31. No abstract available. PubMed 37649400 ↗
  • Li X, Zhu H, Fan X, Wang Q, Wang Z, Li H, Tao J, Wang H, Liu Z, Yao Y. Tricuspid regurgitation outcomes in left bundle branch area pacing and comparison with right ventricular septal pacing. Heart Rhythm. 2022 Jul;19(7):1202-1203. doi: 10.1016/j.hrthm.2022.03.005. Epub 2022 Mar 10. No abstract available. PubMed 35278699 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2025; primary completion for Mar 2026, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2025
First posted
Apr 10, 2025
StartEst.
Apr 2025
Primary completionEst.
Mar 2026
CompletionEst.
May 2026
Last update
Apr 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06922526
Lead sponsor
Haiyan Wang
Responsible party
Haiyan Wang (Director, Qianfoshan Hospital) — Sponsor-investigator
First posted
Apr 10, 2025
Start date
Apr 2025 (estimated)
Primary completion
Mar 2026 (estimated)
Completion
May 2026 (estimated)
Last update
Apr 30, 2025

Study contacts

Haiyan Wang, MD
Contact
wanghaiyan96@126.com
86-13583184107
Haiyan Wang, MD
principal investigator · The First Affiliated Hospital of Shandong First Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion